Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI

Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI

Background: The first goal of the study was to analyse the antibody titre 21 days after the first dose of the BNT162b2 vaccine in a group of 252 healthcare workers (HCW). The second goal was to analyse how the antibody titre changes in correlation with age, gender and body mass index (BMI). Methods:...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccines (Basel) 2021-06, Vol.9 (7), p.685
Hauptverfasser: Pellini, Raul, Venuti, Aldo, Pimpinelli, Fulvia, Abril, Elva, Blandino, Giovanni, Campo, Flaminia, Conti, Laura, De Virgilio, Armando, De Marco, Federico, Di Domenico, Enea Gino, Di Bella, Ornella, Di Martino, Simona, Ensoli, Fabrizio, Giannarelli, Diana, Mandoj, Chiara, Manciocco, Valentina, Marchesi, Paolo, Mazzola, Francesco, Moretto, Silvia, Petruzzi, Gerardo, Petrone, Fabrizio, Pichi, Barbara, Pontone, Martina, Zocchi, Jacopo, Vidiri, Antonello, Vujovic, Branka, Piaggio, Giulia, Morrone, Aldo, Ciliberto, Gennaro
Format: Artikel
Sprache:eng
Schlagworte:
Age
Antibodies
Antigens
Body mass
Body mass index
Body size
Brief Report
Clinical trials
Coronaviruses
COVID-19
COVID-19 vaccines
Cytokines
Disease transmission
Gender
Immune response
Immune system
Immunoassay
Infections
Medical personnel
Medical research
mRNA vaccines
Multivariate analysis
Obesity
Population
Priming
SARS-CoV-2
serum titer
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Statistical analysis
Underweight
vaccine
Vaccines
Weight
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: The first goal of the study was to analyse the antibody titre 21 days after the first dose of the BNT162b2 vaccine in a group of 252 healthcare workers (HCW). The second goal was to analyse how the antibody titre changes in correlation with age, gender and body mass index (BMI). Methods: Participants had a nasopharyngeal swab for SARS-CoV-2 and were assessed for the presence of SARS-CoV-2 antibodies at baseline and 21 days after the BNT162b2 priming dose. Results: First dose of BNT162b2 activated immune responses in 98% of the participants. Five HWC had no increase in antibody titre 21 days after the first dose. Antibody titre was greater in young (
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines9070685